rivastigmine patch
Recently Published Documents


TOTAL DOCUMENTS

91
(FIVE YEARS 6)

H-INDEX

12
(FIVE YEARS 1)

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mehmet Ilkin Naharci ◽  
Betul Gulsum Yavuz Veizi ◽  
Bilal Katipoglu ◽  
Ece Akcan ◽  
Fatma Yoruk ◽  
...  

2019 ◽  
Vol 236 (4) ◽  
pp. 1255-1260 ◽  
Author(s):  
Ping-Song Chou ◽  
Kai-Ming Jhang ◽  
Ling-Chun Huang ◽  
Wen-Fu Wang ◽  
Yuan-Han Yang

2018 ◽  
Vol 53 (5) ◽  
pp. 292-295
Author(s):  
Michael A. Mancano ◽  
Kristen J. Milenki ◽  
Morgan V. Esordi ◽  
Darshil D. Patel

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of revention, and promote reporting of ADRs to the US Food and Drug Administration’s (FDA) MedWatch program (800-ßDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with ur readers. E-mail [email protected] ). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA’s MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.


2018 ◽  
Vol Volume 12 ◽  
pp. 1247-1252 ◽  
Author(s):  
Takashi Osada ◽  
Norio Watanabe ◽  
Naomitsu Asano ◽  
Yuzo Adachi ◽  
Keiko Yamamura

2018 ◽  
Vol 38 (3) ◽  
pp. 281-282 ◽  
Author(s):  
Mehmet Ilkin Naharci ◽  
Ilker Tasci
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document